Vault Complexes for Cytokine Delivery in Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for delivering cytokines like CCL-21 for cancer immunotherapy, such as using autologous dendritic cells, are cumbersome, expensive, and suffer from batch-to-batch variability and lack of standardization, limiting their clinical effectiveness.
Innovation Solution
Development of vault complexes that encapsulate cytokine fusion proteins, specifically CCL-21 fused with a major vault interaction domain, allowing for efficient intratumoral delivery and activation of immune responses without the need for autologous dendritic cell preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous dendritic cells are used for cytokine delivery, then immune response activation is achieved, but the process becomes cumbersome and expensive with batch-to-batch variability
Solution Approach 1:
The patent uses vault complexes as an intermediary delivery vehicle to transport CCL-21 cytokine directly to tumor sites, eliminating the need for complex autologous dendritic cell preparation while maintaining immune response activation. The vault complex serves as a standardized mediator that simplifies the delivery process.
Solution Approach 2:
The invention creates a standardized vault complex model that copies the desirable immune-stimulating function of dendritic cells without requiring the complex biological preparation process. This standardized model eliminates batch-to-batch variability while preserving the therapeutic effect.
2Reliability
If high and frequent dosing of recombinant CCL-21 is administered, then antitumor response is induced, but systemic toxicity increases and clinical effectiveness is limited
Solution Approach 1:
The vault complex is designed to deliver CCL-21 specifically to the tumor microenvironment, creating localized high concentration at the target site while maintaining low systemic levels. This spatial differentiation of drug concentration achieves effective tumor response with reduced systemic toxicity.
Solution Approach 2:
The vault complex acts as a targeted intermediary that delivers CCL-21 specifically to tumor sites through intratumoral injection, preventing widespread systemic distribution. This targeted delivery mechanism reduces off-target effects and systemic toxicity while maintaining therapeutic efficacy.
3Reliability
If proteins are administered intratumorally, then local immune response is stimulated, but the proteins are not retained locally for prolonged periods
Solution Approach 1:
The CCL-21 cytokine is nested within the vault complex structure, creating a protected composite delivery system. This nesting allows the protein to be retained at the injection site longer and delivered gradually to target cells, extending the duration of local immune response stimulation.
Solution Approach 2:
The invention uses a composite delivery system where CCL-21 protein is combined with vault complex particles. This composite structure enhances local retention time compared to naked protein, allowing prolonged stimulation of local immune responses at the tumor site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vault complexes effectively stimulate immune responses, increasing T cell migration and reducing tumor burden, offering a more efficient and standardized approach to cancer treatment compared to traditional methods.
Implementation Method 1
vault complexes that encapsulate cytokine fusion proteins, specifically CCL-21 fused with a major vault interaction domain, allowing for efficient intratumoral delivery
Data Source
AI summary
The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.